

美洲華人生物科學學會

Society of Chinese Bioscientists in America Bio/Pharm Division

May, 2005

Newsletter

Volume 13

Issue 1

Letter from new President

I am honored by the vote of confidence of the BioPharm Board of Directors to be elected the President of the SCBA BioPharm Division with effect from 2005. I wish to take this opportunity to thank Wei-Chi Liao who had done a great job together with his operating council in leading the BioPharm Division since 2002. I look forward to working with the Board of Directors and the operating council to serve the BioPharm members to further our common goals.

The SCBA BioPharm Division is a voluntary, member-driven organization. There is a great diversity in our membership. Most are based in industry or academia, some are biologists, some are chemists, and some are clinically qualify while others are business savvy. Our younger members include graduate students and post-docs while our senior members include those who maintain their interest in our Division in their retirement. This diversity has greatly enriched our Division and provides an excellent networking environment to meet bioscientists from academia, industry and government. The success of our division is directly related to the active involvement of our members in our activities. Going forward, I encourage you to ask not what the Division can do for you but what we **can do together** to advance our common goals. I ask you to give me your help, your voice and your support. If you are interested in volunteering to help with the divisional activities (e.g. organizing meetings, fund-raising, contributing articles, etc), please feel free to contact myself or any of the operating council members below. I am confident that with your

support, we will make our division a strong and fun organization to work with.

The Operating council 2005:

It gives me great pleasure to announce the following members have agreed to serve on the operating council in 2005:

President: Chi-Ming Lee, AstraZeneca, 302-885-0669, chi-ming.lee@astrazeneca.com

Conf. Planning: Yen-Huei Lin, Wyeth Lab, 845-602-3879, Liny3@wyeth.com

Membership: Wen-lang Yang, A. Einstein Coll Med718-430-3772, wlyang@ecom.yu.edu

Website: Lai-shun Chen, Bristol-Myers Squibb 609-252-4598 chenls@yahoo.com

Quarterly: Lu-hai Wang, Mt. Sinai Med Ctr212-241-3795, lu-hai.wang@mssm.edu

Fundraising: Tong Kong, Rutgers Coll Pharm 732-445-7335, KongT@rci.rutgers.edu

Newsletter: Jay Liu, AstraZeneca, 302-886-2667, jay.liu@astrazeneca.com

Finance: Paul Hsia, China Health Gp, 630-865-3388, pthsia@aol.com

Treasury: Jason Chen, J. Chen & Asso. LLC, 732-846-6567, jason@jasonchencpa.com

I would like to take this opportunity to thank Shih-jung Lan for his excellent service on the operating council since 2002 and to extend a warm welcome to Jay Liu who will succeed Shih-jung as chairperson of the Newsletter committee.

~~ Chi-Ming Lee

Results of SCBA BioPharm Board election:

Shing Chang, the Chairperson of the BioPharm Board, would like to take this opportunity to inform you the results of the recent Board election. Shing will continue to work with the Board (members and terms are indicated in the table below) to streamline its work process and to complete the bylaw for the Division.

| Term | Name |
|---------------------------|-----------------|
| 3 year ending in Dec 2007 | Wei-chi Liao |
| 3 year ending in Dec 2007 | Ronson Lin |
| 3 year ending in Dec 2007 | Henry Pan |
| | |
| 2 year ending in Dec2006 | Yung-chi Cheng |
| 2 year ending in Dec2006 | Nehemiah Cherng |
| 2 year ending in Dec2006 | Horace Loh |
| | |
| 1 year ending in Dec2005 | Xiao Fan Wong |
| 1 year ending in Dec2005 | Hardy Chan |
| 1 year ending in Dec2005 | Juilien Huang |
| 1 year ending in Dec2005 | Shing Chang |

Upcoming events:

• June 18: SAPA-GP Annual Conference

To further our collaboration with the Sino-American Pharmaceutical Professionals Association (SAPA) since our conference in Shanghai last year, we will be **co-sponsoring the Third SAPA-Greater Philadelphia Chapter Annual Conference** in Blue Bell, Pennsylvania on **18 June 2005**. Active members of SCBA/BioPharm division will receive a discount in registration fee (from \$45 for non-member to \$25 for SCBA/BioPharm member). The program for the meeting is included below for your information. In addition to a strong scientific program, the conference also provides a great opportunity to learn the recent Pharmaceutical/Biotech R&D activities in

China. For your convenience, we have included a link to the SAPA-GP website for you to register for the Conference* and Dinner Reception**: www.sapa-gp.org

Please note that the on-line registration will be on a first-come first-serve basis. To receive the discount for registration fee, please check the box to confirm you are a member of SCBA/BioPharm division. The registration fee includes attendance of the scientific program, breakfast, coffee and lunch but not dinner. You can select to pay by credit card online or by cheque. * The capacity of the conference auditorium is limited to 370 attendees and on-line registration will be closed once it reaches the full capacity.

** The capacity of the dinner reception is limited to 200 people and on-line registration will be closed once it reaches the full capacity.

Third SAPA-GP Annual Conference: Globalization of Pharmaceutical/Biotech R&D

Saturday, June 18, 2005

Science Center, [Montgomery County Community College](#), 340 Dekalb Pike, Blue Bell, Pennsylvania, 19422

[Registration](#) & Breakfast – 7:40-8:30 am

Han-Cheng Zhang, Ph. D.

President of SAPA-GP & Conference Chair

Opening Remarks

Session 1: Current Trends in World Pharmaceutical/Biotech Industry (8:40 - 11:20 am)

Keynote Speakers

Anthony Ford-Hutchinson, Ph.D.

Executive Vice President, Worldwide Basic Research, Merck Research Laboratories, Merck & Co., Inc

Current Challenges and Opportunities of Global Drug Discovery

Baruch S. Blumberg, M.D., Ph.D

Nobel Prize Laureate in Medicine, Fox Chase Distinguished Scientist, Senior Advisor to President, Fox Chase Cancer Center

Global Issues and Infectious Disease. The Worldwide Hepatitis B Vaccination Campaign

Jose V. Sartarelli, Ph.D.

Company Group Chairman, Asia-Pacific/Japan/Latin America, Johnson & Johnson Pharmaceuticals Group

Prospects for Asia-Pacific and China. A World of Possibilities

Ted Chin

Vice President, Biomedical Data Sciences, Worldwide Development, GlaxoSmithKline

TBA

Robert R. Ruffolo, Jr., Ph.D.

President, Research & Development, Wyeth Pharmaceuticals, Senior Vice President, Wyeth Corporation

Strategies to Integrate Discovery, Development and Global Marketing

SAPA-GP Award Presentation

SAPA-GP Election Results Announcement (11:20 -11:30 am)

Han-Cheng Zhang, Ph.D., Li Shi, Ph.D.

President, SAPA-GP & Conference Chair President-elect, SAPA-GP & Conference Co-Chair

Lunch Break (11:30 am– 12:30 pm)

Session 2: Global R&D Alliance and Outsourcing (12:30 – 3:10 pm)

(All presentations will be delivered in English)

Keynote Speakers

Ling Chen, M.D., Ph.D.

Director-General, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences

An East-West Partnership in Innovative Medicine, Has the Time Arrived?

Ken Fong, Ph.D.

Chairman, Kenson Ventures, Founder of Clontech

Biotech and Pharmaceutical Development in China and US - Opportunities and Challenges

George Blumberg, Ph.D.

Director, Blumberg Associates Limited, Oxford Centre for Innovation, Oxford, UK

The Growth and Competitiveness of the European Union and its Biotech Industry

Ling Su, Ph.D.

Director, Medical and International Pharma Development, Shanghai Roche Pharmaceuticals Ltd

Drug Clinical Development in Asia and China

Kewen Jin, Ph.D.

CEO, Shanghai BioExplorer

Pre-clinical Service - A New Area of Offshore R&D Outsourcing

Nathan Xin Zhang, Ph.D.

Chairman and CEO, Sinocro Partners

Investing into Chinese Life Science Industry

Bill Guo, Ph.D.

CEO and President, Venturepharm Holdings Ltd.

Opportunities for Outsourcing of Integrated Pharmaceutical Development in China

Ge Li, Ph.D.

Chairman and CEO, Wuxi PharmaTech Co., Ltd

R&D Outsourcing in China

Session 3: Chinese Biotech/Pharma: Challenges and Opportunities (3:20 – 6:00pm)

(Presentations will be delivered in English and Chinese)

Keynote Speakers

Hongguang Wang, Ph.D.

Director-General, China National Center for Biotechnology Development, The Ministry of Science and Technology of China

Biotechnology and Bioindustry in China

Ming-De Yu

Executive Chairman, China Worldbest Life Industry Co, Executive Chairman, China Pharmaceutical Enterprise Management Association and China Pharmaceutical Enterprise Directors Association

Current Status and Prospects of Chinese Pharmaceutical Industry

Huacheng Wei, MBA

Chairman, Beijing Pharmaceutical Group Co.

Cooperation, Development and Stepping Forward

Jingkang Shen, Ph.D.

Deputy Director, Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Drug discovery and development at Shanghai Institute of Materia Medica

Jing Cheng, Ph.D.

CEO and CTO, CapitalBio Corporation

Start-up Biotech Companies and Global Collaborations in China

Xian-Ping Lu, Ph.D.

Co-Founder, Director, and Chief Scientific Officer,
Shenzhen Chipscreen Biosciences

Modern Drug Discovery and Development Efforts by Chinese Biopharmaceutical Industry

Yin Luo, Ph.D., MBA

President and CEO, Shanghai Genomics, Inc

How to Balance Between Research Budget and Revenue Growth in Chinese Biotech Start-up

Yongzheng Hui

Chairmen and President of Shanghai Innovation Center of Traditional Medicine, Former Deputy Minister, The Ministry of Science and Technology of China

Globalization of Chinese Medicine

Panel Discussion (6:00 – 6:40 pm)

Shanghai Zhangjiang Night Dinner Reception (6:40 – 9:00 pm)

(上海张江之夜招待会 Sponsored by Zhangjiang Hi-Tech Park)

(College Hall, Montgomery County Community College, only 2 min walking from conference auditorium)

The reception will provide a great networking opportunity among speakers, attendees, sponsors, Shanghai Zhangjiang delegation (consisting of 10 people) and other delegations from China. Drinks and gourmet Italian buffet dinner will be served, along with a live music band performance.

During the reception, there will be a 30-min presentation by Zhangjiang delegation to introduce Shanghai Pudong New Area and Zhangjiang National Biotech & Pharmaceutical Base.

• Mont Jade Event on June 18

Dr. Johnsee Lee, President of Industrial Technology Research Institute (ITRI) will deliver an overview of Taiwan Biotech Industry at the Taiwan-US Biotech Dinner Seminar on June 18, 2005 in Philadelphia. This seminar is organized by Global Monte Jade, ITRI and Taiwan Bio Industry Organization. Please visit www.mjma.org for more information.